Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
An increase in Intersect ENT's (XENT) operating costs puts pressure on its Q3 bottom line.